Evidence map›Paper›PMID 40623177›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.

Megan B Barnet, Katherine J L Jackson, Etienne Masle-Farquhar, Amanda Russell, Deborah L Burnett, Adrian Chye, Chris J Jara, Megan Faulks, Amanda Mawson, Timothy J Peters and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Contrasting outcomes of inheritedProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Megan B Barnet *Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.ORCID 0000-0003-3243-2716
Katherine J L Jackson *Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Etienne Masle-FarquharImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Amanda RussellImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Deborah L BurnettImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.ORCID 0000-0002-5642-3315
Adrian ChyeImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Chris J JaraImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Megan FaulksImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Amanda MawsonImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Timothy J PetersImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Robert BrinkImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Katherine WrightDepartment of Medical Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Darlinghurst, NSW 2010, Australia.
India AllenImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Simon JunankarImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Ian D DavisSchool of Medicine, Monash University, Clayton, VIC 3800, Australia.
Gillian HellerNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia.
Zia KhanGenentech, South San Francisco, CA 94080-4990.
Jeffrey BrucePrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Cindy YangPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Stephenie ProkopecPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Trevor PughPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Andreas BehrenOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
Georgina L HoldUNSW Microbiome Research Centre, University of New South Wales Sydney, Kogarah, NSW 2217, Australia.
Fan ZhangUNSW Microbiome Research Centre, University of New South Wales Sydney, Kogarah, NSW 2217, Australia.
Wendy A CooperSchool of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.
Bo GaoBlacktown Cancer and Haematology Centre, Blacktown Mount Druitt Hospital, Blacktown, NSW 2148, Australia.
Adnan NagrialSydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
Anthony M JoshuaImmunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Thomas JohnPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Geoffrey PetersCanberra Region Cancer Centre, Garran, ACT 2605, Australia.
Rina HuiSchool of Clinical Medicine, Hong Kong University Health System, Hong Kong.
Michael BoyerSydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
Prunella L BlinmanSydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
Steven C KaoSydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
Jonathan Cebon *Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
Christopher C Goodnow *Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.ORCID 0000-0001-5296-6155

Funding

Bill and Patricia Ritchie Foundation no grant numberBioplatforms Australia (Bioplatforms) no grant numberKinghorn Foundation (The Kinghorn Foundation) no grant numberNHMRC APP2010134
6 · The paper itself

Abstract

Lung cancers and melanomas have many somatically mutated self-proteins that would be expected to trigger an immune rejection response, yet therapeutic responses can only be induced in a subset of patients. Here, we investigated the possibility that inherited differences in immune tolerance checkpoints contribute to variability in outcomes. Whole genome sequencing revealed biallelic germline loss-of-function (LOF) mutations in the immune tolerance checkpoint gene,

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLoss of Function MutationLung NeoplasmsNod2 Signaling Adaptor ProteinAnimalsFemaleGerm-Line MutationHumansMaleMelanomaMiceProgrammed Cell Death 1 ReceptorNOD2 protein, humanNod2 Signaling Adaptor ProteinProgrammed Cell Death 1 Receptorautoimmune diseasecancer immunotherapyimmune checkpoint inhibitorimmune-related adverse eventinherited variant

Identifiers

PMID40623177
PMCPMC12280981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.